Integrative analysis on the effects of streptozotocin in the experimental model for diabetization in wistar rats: histological and laboratory study
DOI:
https://doi.org/10.34119/bjhrv7n2-171Keywords:
animal model, diabetes, insulin, metabolic alterationsAbstract
The study of complications of diabetes mellitus is important to understand the alterations on the specific tissues affected by this chronic disease. An animal model that simulated this complication is necessary for further treatments and prevention of diabetes complications. The aim of this study was evaluated the biochemical and histological alterations on liver, kidney, small gut and retina tissues. The animal assay was made with 15 wistar rats divided in two groups: a control group, consisting of 5 rats that were healthy and non-diabetic (CONTROL), and a streptozotocin group (STZ), consisting of 10 rats who were diabetic. A dosage of streptozotocin at a concentration of 40 mg/kg was administered intraperitoneally. Rats with glycemia levels below 150 mg/dl received a subsequent injection of 40 mg/kg of streptozotocin, whereas rats with glycemia levels ranging from 150 to 250 mg/dl were given a subsequent injection of 20 mg/kg of streptozotocin. The biochemical results showed difference in triglyceride, AST and ALT levels between the groups. The histological analysis of liver, kidney, small gut and retina showed significant alterations related to the chronic diabetes complications. These results suggested that this animal model can be used for future studies of metabolics mechanisms to undertand and avoid the complications of diabetes.
References
Conget I. Diagnóstico, clasificación y patogenia de la diabetes mellitus. Revista española de cardiología. 2002 Jan 1;55(5):528-35.
Federation ID. IDF diabetes atlas, tenth. International Diabetes. 2021
Lerco MM, Spadella CT, Machado JL, Schellini SA, Padovani CR. Caracterização de um modelo experimental de Diabetes Mellitus, induzido pela aloxana em ratos: estudo clínico e laboratorial. Acta Cirúrgica Brasileira. 2003;18:132-42.
Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxicity: specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov 1;43(11):1326-33.
Bolzán AD, Bianchi MS. Genotoxicity of streptozotocin. Mutation Research/Reviews in Mutation Research. 2002 Dec 1;512(2-3):121-34.
Takasu N, Komiya I, Asawa T, Nagasawa Y, Yamada T. Streptozocin-and alloxan-induced H2O2 generation and DNA fragmentation in pancreatic islets: H2O2 as mediator for DNA fragmentation. Diabetes. 1991 Sep 1;40(9):1141-5.
Silva M, Lima WG, Silva ME, Pedrosa ML. Efeito da estreptozotocina sobre os perfis glicêmico e lipídico e o estresse oxidativo em hamsters. Arquivos Brasileiros de Endocrinologia & Metabologia. 2011;55:46-53.
Anderson HR, Stitt AW, Gardiner TA, Lloyd SJ, Archer DB. Induction of alloxan/streptozotocin diabetes in dogs: a revised experimental technique. Laboratory animals. 1993 Jul 1;27(3):281-5.
Hughes WF. Quantitation of ischemic damage in the rat retina. Experimental eye research. 1991 Nov 1;53(5):573-82.
King AJ. The use of animal models in diabetes research. British journal of pharmacology. 2012 Jun;166(3):877-94.
Schebelski DJ, Lipinski L, Moreira Junior CA, Koga AY, Carletto B, Montemor MM, Farago PV, Gomes RZ. Cilostazol protects against changes caused by streptozotocin-induced diabetic retinopathy. Arquivos Brasileiros de Oftalmologia. 2022 Jul 15.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological research. 2001 Jan 1;50(6):537-46.
da Silva NR, da Costa CE. A hiperglicemia e os mecanismos envolvidos nas disfunções vasculares do Diabetes Mellitus. Arquivos de Ciências da Saúde da UNIPAR. 2008;12(3).
Twarda-Clapa A, Olczak A, Białkowska AM, Koziołkiewicz M. Advanced glycation end-products (AGEs): Formation, chemistry, classification, receptors, and diseases related to AGEs. Cells. 2022 Apr 12;11(8):1312.
Takada J, Machado MA, Peres SB, Brito LC, Borges-Silva CN, Costa CE, Fonseca-Alaniz MH, Andreotti S, Lima FB. Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance associated with loss of adipose mass. Metabolism. 2007 Jul 1;56(7):977-84.
Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013 Sep 30;4(4):46-57.
Carvalheira JB, Zecchin HG, Saad MJ. Vias de sinalização da insulina. Arquivos Brasileiros de Endocrinologia & Metabologia. 2002;46:419-25.
Matheus AS, Cobas RA, Gomes MB. Dislipidemias no diabetes melito tipo 1: abordagem atual. Arquivos Brasileiros de Endocrinologia & Metabologia. 2008;52:334-9.
Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. Diabetes therapy. 2016 Jun;7:203-19.
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2009 Mar;5(3):150-9.
Nogueira Junior FC, Coelho DA, Almeida MM, Silva TC, Ferreira EC, Macedo UB, F Neto FP, Brandão Neto J, Almeida MD, Rezende AA. Efeito do tamoxifeno no perfil lipídico de ratos diabéticos por estreptozotocina. Acta Cirúrgica Brasileira. 2005;20:69-75.
Giestas S, Giestas A, Agostinho C. Doença hepática e diabetes mellitus–uma relação bi-direcional. Revista Portuguesa de Diabetes. 2015;10(4):158-66.
Eleazu CO, Eleazu KC, Chukwuma S, Essien UN. Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. Journal of diabetes & metabolic disorders. 2013 Dec;12:1-7.
Tormo MA, Martínez IM, de Tejada AR, Gil-Exojo I, Campillo JE. Morphological and enzymatic changes of the small intestine in an n0-STZ diabetes rat model. Experimental and clinical endocrinology & diabetes. 2002;110(03):119-23.
Pereira JN, Murata GM, Sato FT, Marosti AR, Carvalho CR, Curi R. Small intestine remodeling in male Goto–Kakizaki rats. Physiological Reports. 2021 Feb;9(3):e14755.
Zhao J, Yang J, Gregersen H. Biomechanical and morphometric intestinal remodelling during experimental diabetes in rats. Diabetologia. 2003 Dec;46:1688-97.
Zoubi SA, Mayhew TM, Sparrow RA. The small intestine in experimental diabetes: cellular adaptation in crypts and villi at different longitudinal sites. Virchows archiv. 1995 Jun;426:501-7.
Trevizan AR, Schneider LC, Araújo EJ, Garcia JL, Buttow NC, Nogueira‐Melo GD, Sant'Ana DD. Acute Toxoplasma gondii infection alters the number of neurons and the proportion of enteric glial cells in the duodenum in Wistar rats. Neurogastroenterology & Motility. 2019 Mar;31(3):e13523.
Lipinski LC, Kmetiuk LB, Mathias PC, Malta A, Favero GM, Ribeiro TA, Toledo A, Netto MR, Rodrigues MR. Oral insulin improves metabolic parameters in high fat diet fed rats. Anais da Academia Brasileira de Ciências. 2017 Aug 31;89:1699-705.
de Rivero Vaccari JP, Lotocki G, Alonso OF, Bramlett HM, Dietrich WD, Keane RW. Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. Journal of Cerebral Blood Flow & Metabolism. 2009 Jul;29(7):1251-61.
Ferreira PE, Lopes CR, Alves AM, Alves ÉP, Linden DR, Zanoni JN, Buttow NC. Diabetic neuropathy: an evaluation of the use of quercetin in the cecum of rats. World Journal of Gastroenterology: WJG. 2013 Oct 10;19(38):6416.
Zhao JB, Frøkjær JB, Drewes AM, Ejskjaer N. Upper gastrointestinal sensory-motor dysfunction in diabetes mellitus. World journal of gastroenterology: WJG. 2006 May 5;12(18):2846.
Kohl T, Gehrke N, Schad A, Nagel M, Wörns MA, Sprinzl MF, Zimmermann T, He YW, Galle PR, Schuchmann M, Schattenberg JM. Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells. Cell death & disease. 2013 Jul;4(7):e712-.
Hsu HC, Dozen M, Matsuno N, Obara H, Tanaka R, Enosawa S. Experimental nonalcoholic steatohepatitis induced by neonatal streptozotocin injection and a high-fat diet in rats. Cell medicine. 2013 Oct;6(1-2):57-62.
Pourghasem M, Shafi H, Babazadeh Z. Histological changes of kidney in diabetic nephropathy. Caspian journal of internal medicine. 2015;6(3):120.
Lau X, Zhang Y, Kelly DJ, Stapleton DI. Attenuation of Armanni–Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Diabetologia. 2013 Mar;56:675-9.
Singh RM, Howarth FC, Adeghate E, Bidasee K, Singh J, Waqar T. Type 1 diabetes mellitus induces structural changes and molecular remodelling in the rat kidney. Molecular and cellular biochemistry. 2018 Dec;449:9-25.
Pourghasem M, Aminian N, Behnam Rasoli M, Nikravesh M, Jalali M. Study of renal glomerular mesangium and volume changes in alloxan induced diabetic rat. Cell Journal (Yakhteh). 2001 Apr 1;3(1):45-9.
Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. European journal of clinical investigation. 2004 Dec;34(12):785-96.
Lai AK, Lo AC. Animal models of diabetic retinopathy: summary and comparison. Journal of diabetes research. 2013 Oct 27;2013.
